Mortality directly related to community-acquired pneumonia (CAP) in hospitalized patients: results from the community-acquired pneumonia organization (CAPO) international cohort study Source: Annual Congress 2007 - Antibiotic treatment in community-acquired pneumonia Year: 2007
Patients‘ characteristics do not influence duration of antibiotic therapy (ABT) in hospitalized patients with community-acquired pneumonia (CAP): results from the CAPO international study Source: Annual Congress 2008 - Treatment and outcome in hospitalised patients with community-acquired pneumonia Year: 2008
The pneumonia severity index (PSI) do not underestimate the severity of community-acquired pneumonia (CAP) in young patients: results from the CAPO international study Source: Annual Congress 2008 - Factors related to outcome of community-acquired pneumonia Year: 2008
Community-acquired pneumonia trough enterobacteriaceae and p. aeruginosa : diagnosis, incidence, and predictors. The German CAPNETZ Source: Annual Congress 2009 - Respiratory infection caused by Pseudomonas aeruginosa Year: 2009
The presence of diabetes does not influence clinical outcomes in patients with community-acquired pneumonia: results from the community-acquired pneumonia organization (CAPO) international cohort study Source: Annual Congress 2007 - Severity scores and comorbidities in community-acquired pneumonia Year: 2007
Could procalcitonin (PCT) be a marker of effectiveness of antibiotic treatment (ABT) in pregnant with not severe community-acquired pneumonia (CAP)? Source: International Congress 2015 – Healthcare organisation and appropriateness in lung disorders Year: 2015
Use of pneumonia severity index in Spain to decide hospitalization among patients with community-acquired pneumonia (CAP). (Nacar Study) Source: Eur Respir J 2005; 26: Suppl. 49, 637s Year: 2005
Significant decrease in long-term survival for hospitalised patients with community-acquired pneumonia (CAP): results from the community-acquired pneumonia organisation (CAPO) international cohort study Source: Annual Congress 2009 - Impact of biomarkers in the management of community-acquired pneumonia Year: 2009
Site of care for community-acquired pneumonia (CAP) patients with CRB-65 score of 0-1 and pneumonia severity index (PSI) risk class (RC) of IV-V: what to do when this discrepancy occurs. Results from the CAPO international study Source: Annual Congress 2008 - Treatment and outcome in hospitalised patients with community-acquired pneumonia Year: 2008
Relevance of correct antibiotic choice in community-acquired pneumonia (CAP) Source: Annual Congress 2005 - Community-acquired pneumonia: clinical approaches Year: 2005
Determinants of performance of indicators on antibiotic use in community-acquired pneumonia (CAP) at hospitals Source: Eur Respir J 2005; 26: Suppl. 49, 638s Year: 2005
Dysnatremia, vasopressin, atrial natriuretic peptide and mortality in community-acquired pneumonia – Results from the German competence network CAPNETZ Source: Annual Congress 2011 - Severity, comorbidities and outcomes in community-acquired pneumonia Year: 2011
Reasons that justify hospitalization for community-acquired pneumonia (CAP) patients with CURB-65 score 0-1 Source: Annual Congress 2008 - Treatment and outcome in hospitalised patients with community-acquired pneumonia Year: 2008
Does the use of the CURB-65 score improve outcomes in community-acquired pneumonia (CAP)? Source: Annual Congress 2009 - Pulmonary infections Year: 2009
Timing of antibiotic administration and outcomes for patients with community-acquired pneumonia (CAP). NAC-CV Study Source: Eur Respir J 2006; 28: Suppl. 50, 349s Year: 2006
Association of CRP values with clinico-radiological appearance in adults with community-acquired pneumonia (CAP) Source: Eur Respir J 2006; 28: Suppl. 50, 374s Year: 2006
Physicians should not use the pneumonia severity index (PSI) or CRB-65 in deciding the need for hospitalization in cancer patients with community-acquired pneumonia (CAP) Source: Eur Respir J 2007; 30: Suppl. 51, 41s Year: 2007
The assessment of prognostic rules in patients with community-acquired pneumonia (CAP) Source: Eur Respir J 2003; 22: Suppl. 45, 149s Year: 2003
Cryptogenic organising pneumonia – clarithromycin treatment – factors influencing treatment results and relapses Source: Annual Congress 2009 - Various backgrounds in diffuse parenchymal lung disease Year: 2009
The analysis of efficiency of amoxycillin/clavulanate (AC) usage at inpatients with community-acquired pneumonia (CAP) Source: Eur Respir J 2006; 28: Suppl. 50, 2s Year: 2006